- CBST has an average dollar-volume (as measured by average daily share volume multiplied by share price) of $51.1 million.
- CBST traded 158,476 shares today in the pre-market hours as of 7:40 AM, representing 31.2% of its average daily volume.
EXCLUSIVE OFFER: Get the inside scoop on opportunities in CBST with the Ticky from Trade-Ideas. See the FREE profile for CBST NOW at Trade-Ideas More details on CBST: Cubist Pharmaceuticals, Inc., a biopharmaceutical company, is engaged in the research, development, and commercialization of pharmaceutical products for medical needs in the acute care environment in the United States. CBST has a PE ratio of 92.6. Currently there are 6 analysts that rate Cubist Pharmaceuticals a buy, 1 analyst rates it a sell, and 5 rate it a hold. The average volume for Cubist Pharmaceuticals has been 627,400 shares per day over the past 30 days. Cubist has a market cap of $5.8 billion and is part of the health care sector and drugs industry. The stock has a beta of 1.56 and a short float of 7.7% with 9.01 days to cover. Shares are up 8.2% year-to-date as of the close of trading on Thursday.
- The net income growth from the same quarter one year ago has significantly exceeded that of the S&P 500 and the Biotechnology industry. The net income increased by 167.3% when compared to the same quarter one year prior, rising from -$33.90 million to $22.83 million.
- CBST's revenue growth trails the industry average of 40.7%. Since the same quarter one year prior, revenues rose by 16.2%. Growth in the company's revenue appears to have helped boost the earnings per share.
- Net operating cash flow has significantly increased by 174.27% to $43.25 million when compared to the same quarter last year. In addition, CUBIST PHARMACEUTICALS INC has also vastly surpassed the industry average cash flow growth rate of 116.43%.
- Compared to where it was a year ago today, the stock is now trading at a higher level, reflecting both the market's overall trend during that period and the fact that the company's earnings growth has been robust. Looking ahead, the stock's rise over the last year has already helped drive it to a level which is relatively expensive compared to the rest of its industry. We feel, however, that the other strengths this company displays justify these higher price levels.
- CUBIST PHARMACEUTICALS INC reported significant earnings per share improvement in the most recent quarter compared to the same quarter a year ago. This company has reported somewhat volatile earnings recently. But, we feel it is poised for EPS growth in the coming year. During the past fiscal year, CUBIST PHARMACEUTICALS INC swung to a loss, reporting -$0.26 versus $2.09 in the prior year. This year, the market expects an improvement in earnings ($1.15 versus -$0.26).
- You can view the full Cubist Pharmaceuticals Ratings Report.